Japan’s rapidly aging population and recent changes to the policy
environment have made reforms to the country’s health care system an
urgent issue. This vision paper outlines the constructive role
innovative biopharmaceutical companies can play to ensure new and
innovative medicines continue to be developed and delivered to Japanese
patients in a timely manner.
This patient-centric approach is
supported by three key pillars: 1) Advancing innovation, 2) Securing
patient access to new innovation in a sustainable universal healthcare
system, and 3) Ensuring policy decisions are evidence based.